AMRN has been granted a new patent
Jul 17, 2024, 10:34 PM
-20.75%
What does AMRN do
Amarin Corp. Plc, a biopharmaceutical company, specializes in developing and commercializing therapeutics aimed at enhancing cardiovascular health, primarily through its lead product, Vascepa. Vascepa, used to lower triglyceride levels in adults with severe hypertriglyceridemia, is distributed mainly to wholesalers and pharmacies.
AMRN filed a patent for "compositions and methods for treating and/or preventing cardiovascular disease" on Wed, March 13, 2024. The patent was officially published on Thu, July 4, 2024.
📡️ Health Care
Patents
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.